Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells

The modified vaccinia virus Ankara (MVA), a severely attenuated strain of vaccinia virus, is a promising vector platform for viral-vectored vaccine development because of its attributes of efficient transgene expression and safety profile, among others. Thus, transgene stability in MVA is important...

Full description

Bibliographic Details
Main Authors: Vajini N. Atukorale, Jerry P. Weir, Clement A. Meseda
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/8/1/137
id doaj-71376b817f6c4709834edbbf9cfca30d
record_format Article
spelling doaj-71376b817f6c4709834edbbf9cfca30d2020-11-25T02:38:13ZengMDPI AGVaccines2076-393X2020-03-018113710.3390/vaccines8010137vaccines8010137Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in CellsVajini N. Atukorale0Jerry P. Weir1Clement A. Meseda2Division of Viral Products, Center for Biologics Evaluation and Research, U S Food &amp; Drug Administration, Silver Spring, MD 20993, USADivision of Viral Products, Center for Biologics Evaluation and Research, U S Food &amp; Drug Administration, Silver Spring, MD 20993, USADivision of Viral Products, Center for Biologics Evaluation and Research, U S Food &amp; Drug Administration, Silver Spring, MD 20993, USAThe modified vaccinia virus Ankara (MVA), a severely attenuated strain of vaccinia virus, is a promising vector platform for viral-vectored vaccine development because of its attributes of efficient transgene expression and safety profile, among others. Thus, transgene stability in MVA is important to assure immunogenicity and efficacy. The global GC content of the MVA genome is 33%, and GC-rich sequences containing runs of C or G nucleotides have been reported to be less stable with passage of MVA vectors in cells. The production of recombinant MVA vaccines requires a number of expansion steps in cell culture, depending on production scale. We assessed the effect of extensive passage of four recombinant MVA vectors on the stability of the GC-rich herpes simplex type 2 (HSV-2) <i>US6</i> gene encoding viral glycoprotein D (gD2) inserted at four different genomic sites, including the deletion (del) II and del III sites, the <i>CP77</i> gene locus (<i>MVA_009&#8722;MVA_013</i>) and the <i>I8R</i>-<i>G1L</i> intergenic region. Our data indicate that after 35 passages, there was a reduction in gD2 expression from del II, del III and <i>CP77</i> sites. Sequencing analysis implicated <i>US6</i> deletion and mutational events as responsible for the loss of gD2 expression. By contrast, 85.9% of recombinant plaques expressed gD2 from the <i>I8R</i>-<i>G1L</i> site, suggesting better accommodation of transgenes in this intergenic region. Thus, the <i>I8R</i>-<i>G1L</i> intergenic region may be more useful for transgene insertion for enhanced stability.https://www.mdpi.com/2076-393X/8/1/137modified vaccinia virus ankaravaccine stabilitytransgenehsv-2
collection DOAJ
language English
format Article
sources DOAJ
author Vajini N. Atukorale
Jerry P. Weir
Clement A. Meseda
spellingShingle Vajini N. Atukorale
Jerry P. Weir
Clement A. Meseda
Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells
Vaccines
modified vaccinia virus ankara
vaccine stability
transgene
hsv-2
author_facet Vajini N. Atukorale
Jerry P. Weir
Clement A. Meseda
author_sort Vajini N. Atukorale
title Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells
title_short Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells
title_full Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells
title_fullStr Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells
title_full_unstemmed Stability of the HSV-2 <i>US-6</i> Gene in the del II, del III, <i>CP77</i>, and <i>I8R</i>-<i>G1L</i> Sites in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vectors in Cells
title_sort stability of the hsv-2 <i>us-6</i> gene in the del ii, del iii, <i>cp77</i>, and <i>i8r</i>-<i>g1l</i> sites in modified vaccinia virus ankara after serial passage of recombinant vectors in cells
publisher MDPI AG
series Vaccines
issn 2076-393X
publishDate 2020-03-01
description The modified vaccinia virus Ankara (MVA), a severely attenuated strain of vaccinia virus, is a promising vector platform for viral-vectored vaccine development because of its attributes of efficient transgene expression and safety profile, among others. Thus, transgene stability in MVA is important to assure immunogenicity and efficacy. The global GC content of the MVA genome is 33%, and GC-rich sequences containing runs of C or G nucleotides have been reported to be less stable with passage of MVA vectors in cells. The production of recombinant MVA vaccines requires a number of expansion steps in cell culture, depending on production scale. We assessed the effect of extensive passage of four recombinant MVA vectors on the stability of the GC-rich herpes simplex type 2 (HSV-2) <i>US6</i> gene encoding viral glycoprotein D (gD2) inserted at four different genomic sites, including the deletion (del) II and del III sites, the <i>CP77</i> gene locus (<i>MVA_009&#8722;MVA_013</i>) and the <i>I8R</i>-<i>G1L</i> intergenic region. Our data indicate that after 35 passages, there was a reduction in gD2 expression from del II, del III and <i>CP77</i> sites. Sequencing analysis implicated <i>US6</i> deletion and mutational events as responsible for the loss of gD2 expression. By contrast, 85.9% of recombinant plaques expressed gD2 from the <i>I8R</i>-<i>G1L</i> site, suggesting better accommodation of transgenes in this intergenic region. Thus, the <i>I8R</i>-<i>G1L</i> intergenic region may be more useful for transgene insertion for enhanced stability.
topic modified vaccinia virus ankara
vaccine stability
transgene
hsv-2
url https://www.mdpi.com/2076-393X/8/1/137
work_keys_str_mv AT vajininatukorale stabilityofthehsv2ius6igeneinthedeliideliiiicp77iandii8riig1lisitesinmodifiedvacciniavirusankaraafterserialpassageofrecombinantvectorsincells
AT jerrypweir stabilityofthehsv2ius6igeneinthedeliideliiiicp77iandii8riig1lisitesinmodifiedvacciniavirusankaraafterserialpassageofrecombinantvectorsincells
AT clementameseda stabilityofthehsv2ius6igeneinthedeliideliiiicp77iandii8riig1lisitesinmodifiedvacciniavirusankaraafterserialpassageofrecombinantvectorsincells
_version_ 1724792137145384960